Article
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.
Shionogi Research Laboratories, Shionogi & Co., Ltd., 12-4, Sagisu, 5-chome, Osaka 553-0002, Japan.
Bioorganic & Medicinal Chemistry Letters (impact factor:
2.55).
08/2007;
17(14):4030-4.
DOI:10.1016/j.bmcl.2007.04.093
pp.4030-4
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease.
[show abstract] [hide abstract]
ABSTRACT: Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease.Mini Reviews in Medicinal Chemistry 06/2009; 9(5):539-59. · 2.53 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
moderate activity
novel class
potent agonists
potent compound 13 displays K(i)
Structure-activity relationships